OBT-076 is under clinical development by Oxford BioTherapeutics and currently in Phase I for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer). According to GlobalData, Phase I drugs for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) have a 90% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how OBT-076’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
OBT-076 overview
OBT-076 is under development for the treatment of solid tumor, her2 negative breast cancer, a type of non-Hodgkin lymphoma (NHL), Adenoid Cystic Carcinoma (ACC) of the head and neck, gastric cancer, endometrial cancer, non-small cell lung (NSCLC) cancer, and ovarian cancer and bladder cancers. It is administered through intravenous route as a solution. It is an antibody-drug conjugate (ADC) composed of fully humanized IgG1 monoclonal antibody conjugated to a potent cytotoxic maytansin toxin through a cleavable linker. ADC acts by targeting a type I transmembrane glycoprotein and a C-type lectin receptor Ly75/ CD205. It is being developed based on Oxford Genome Anatomy Project (OGAP) technology.
It was also pancreatic cancer, triple negative breast cancer and diffuse large B-cell lymphoma (DLBCL).
Oxford BioTherapeutics overview
Oxford BioTherapeutics (OBT) is a clinical-stage oncology company that develops antibody-drug conjugates for the treatment of a variety of cancers. The company’s product pipelines currently include T-cell-based IO therapies including checkpoint modulators; NK cell-based IO therapies such as antibody-dependent cell-mediated toxicity (ADCCs); and Antibody-drug conjugates (ADCs). Its therapeutic antibodies target checkpoints to restore anti-tumour immune function allowing the immune system to recognize and kill cancer cells. The company works in collaboration with companies for the development of component technologies to develop innovative ADCs. It operates in the UK and Switzerland. Oxford BioTherapeutics is headquartered in Abingdon, the UK.
For a complete picture of OBT-076’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
